LEERINK
CENTER FOR PHARMACOECONOMICS

READ THE REPORT

Desmoid Tumors

We compared the health-adjusted life expectancy, medical costs, and workforce participation between an average person living with a treatment-indicated desmoid tumor receiving symptom management and a comparable person from the US general population. The differences between the two represent the unmet need and define the health and economic opportunity for desmoid tumor innovation.

PATIENT OPPORTUNITY

Increase health-adjusted life expectancy

6.7 discounted health-adjusted life years to recover

$2-$7.5M value from improved health per person

HEALTH SYSTEM OPPORTUNITY

Reduce disease-related medical costs

$320K of specialist care, serial imaging, clinic visits, laboratory monitoring, and hospitalizations

$320K disease-related medical costs to avoid

ECONOMIC OPPORTUNITY

Restore workforce productivity

5.3 full-time-equivalent years of productivity to recover

$540K additional paid labor production

ANALYTIC APPROACH AND CONTEXT

The report is about the broader progress that innovation in the desmoid tumor treatment landscape could provide, not about the reimbursement or pricing of specific therapeutics. The analysis compares estimated outcomes for an average person living with a treatment-indicated desmoid tumor receiving symptom management to a comparable person in the general US population. Gaps in health-adjusted life expectancy, medical costs, and workforce participation were monetized and discounted at a 3% discount rate. All monetary estimates are in 2025 US dollars. Importantly, societal value estimates by stakeholder group may not be additive, this is not a comprehensive assessment of all societal impacts of desmoid tumors, and the results are sensitive to the occurrence of spontaneous regression over the long-term. Read the full report for more information.

AUTHOR:
Melanie D. Whittington, PhD, MS
Managing Director and Head
Leerink Center for Pharmacoeconomics

Disclosures

The Center for Pharmacoeconomics ("CPE") is a division of MEDACorp LLC ("MEDACorp"). CPE is committed to advancing the understanding and evaluating the economic and societal benefits of healthcare treatments in the United States. Through its thought leadership, evaluations, and advisory services, CPE supports decisions intended to improve societal outcomes. MEDACorp, an affiliate of Leerink Partners LLC ("Leerink Partners"), maintains a global network of independent healthcare professionals providing industry and market insights to Leerink Partners and its clients. The information provided by the Center for Pharmacoeconomics is intended for the sole use of the recipient, is for informational purposes only, and does not constitute investment or other advice or a recommendation or offer to buy or sell any security, product, or service. The information has been obtained from sources that we believe reliable, but we do not represent that it is accurate or complete and it should not be relied upon as such. All information is subject to change without notice, and any opinions and information contained herein are as of the date of this material, and MEDACorp does not undertake any obligation to update them. This document may not be reproduced, edited, or circulated without the express written consent of MEDACorp.